Nab-Paclitaxel and Durvalumab With or Without Neoantigen Vaccine in Treating Patients With Metastatic Triple Negative Breast Cancer
Conditions: Anatomic Stage IV Breast Cancer AJCC v8; Estrogen Receptor Negative; HER2/Neu Negative; Metastatic Triple-Negative Breast Carcinoma; Progesterone Receptor Negative; Prognostic Stage IV Breast Cancer AJCC v8 Interventions: Drug: Carboplatin; Biological: Durvalumab; Drug: Gemcitabine Hydrochloride; Drug: Nab-paclitaxel; Biological: Personalized Synthetic Long Peptide Vaccine; Drug: Poly ICLC Sponsor: National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Cancer Vaccines | Carcinoma | HER2 | Vaccines